Commentary

Ketamine formulation study is ‘groundbreaking’

Publish date: April 24, 2018

 

References

1. Biol Psychiatry. 2016 Sep 15;80(6):424-31.

2. JAMA Psychiatry. 2018 Feb 1;75(2):139-48.

3. Am J Psychiatry. 2018 Apr 16. doi: 10.1176/appi.ajp.2018.17060720.

4. Am J Psychiatry. 2018 Apr 1;175(4]):327-35.

5. Psychol Med. 2015 Dec;45(16):3571-80.

6. Am J Psychiatry. 2018 Feb 1;175(2):150-8.

7. Am J Psychiatry. 2016 Aug 1;173(8):816-26.

Pages

Recommended Reading

Serotonin syndrome risk with triptans and antidepressants ‘very low’
MDedge Internal Medicine
Insomnia, major depressive episode linked in U.S. soldiers
MDedge Internal Medicine
Depression risks identified in women
MDedge Internal Medicine
Consanguineous parentage raises risk of mood disorders, psychoses in offspring
MDedge Internal Medicine
Rosacea tied to physical and psychological comorbidities
MDedge Internal Medicine
Esketamine nasal spray brings fast relief of depressive symptoms
MDedge Internal Medicine
Change in approach advised for treatment-resistant depression
MDedge Internal Medicine
Focus on early maladaptive schemas can reduce PTSD burden
MDedge Internal Medicine
Suicide prevention, NRA team up for safer gun storage
MDedge Internal Medicine
Suicide on the minds of many Utah teens
MDedge Internal Medicine